What do we mean by “value creation” and what does it have to do with Pathology and quality?
First, some background...
At its core is maximizing value for patients: that is, achieving the best outcomes at the lowest cost. We must move away from a supply-driven health care system organized around what physicians do and toward a patient-centered system organized around what patients need. We must shift the focus from the volume and profitability of services provided—physician visits, hospitalizations, procedures, and tests—to the patient outcomes achieved. And we must replace today’s fragmented system, in which every local provider offers a full range of services, with a system in which services for particular medical conditions are concentrated in health-delivery organizations and in the right locations to deliver high-value care. —Porter, Michael E., and Thomas H. Lee. "The Strategy That Will Fix Health Care." Harvard Business Review 91, no. 10 (October 2013): 50–70.
Value Creation and Pathology
One of the core directives for the Division of Quality and Health Improvement is to explore initiatives within the Department of Pathology and across the University of Michigan Health System to position Pathology as a valuable member of a patient’s care team. The fact that lab results influence about 70% of medical decisions makes it imperative that we collaborate with our clinical partners to ensure this information is at the center of patient care.
One example of this type of initiative currently underway is a collaboration among the Department of Internal Medicine, Emergency Department, and Department of Pathology to investigate the utilization of troponin testing to determine whether UMHS as an institution might improve its utilization of this test. Troponin is a protein found in heart muscle and is released into the blood when there is damage to the heart. Therefore troponin tests are primarily ordered to help diagnose a heart attack. The goal of this team is to ensure each round of testing helps the clinician make better decisions and decrease testing that is clinically unnecessary.